BioCentury
ARTICLE | Clinical News

Ixiaro regulatory update

May 27, 2013 7:00 AM UTC

Intercell said FDA approved Ixiaro Japanese Encephalitis (JE) vaccine to include pediatric patients. The product is marketed for adults as Ixiaro in Canada, Europe, Hong Kong, Israel, Singapore and the U.S., where it has Orphan Drug designation, and as Jespect in Australia and New Zealand. The European Commission approved the pediatric indication in February (see BioCentury, Feb. 18). In December, Intercell said it would merge with Vivalis S.A. (Euronext:VLS, Nantes, France). The merger is expected to close on May 28 (see BioCentury, Dec. 24, 2012). ...